Evidence map›Paper›PMID 41876881›Full record

ArticleApplied microbiology and biotechnology2026

Development of canine parvovirus-neutralizing monoclonal antibodies from natural host and their germline gene usage.

Guo Liu, Pengfei Fu, Xiaoli Zhang, Fanli Kong, Jie Peng, Di Kang, Yuqi Pei, Kun Li, Zengjun Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guo LiuCollege of Veterinary Medicine, Gansu Agricultural University, No. 1 Yingmencun, Anning District, Lanzhou, 730070, China. liug@gsau.edu.cn.
Pengfei FuCollege of Life Science and Engineering, Henan University of Urban Construction, Pingdingshan, 467036, China.
Xiaoli ZhangCollege of Veterinary Medicine, Gansu Agricultural University, No. 1 Yingmencun, Anning District, Lanzhou, 730070, China.
Fanli KongCollege of Veterinary Medicine, Gansu Agricultural University, No. 1 Yingmencun, Anning District, Lanzhou, 730070, China.
Jie PengCollege of Veterinary Medicine, Gansu Agricultural University, No. 1 Yingmencun, Anning District, Lanzhou, 730070, China.
Di KangCollege of Veterinary Medicine, Gansu Agricultural University, No. 1 Yingmencun, Anning District, Lanzhou, 730070, China.
Yuqi PeiCollege of Veterinary Medicine, Gansu Agricultural University, No. 1 Yingmencun, Anning District, Lanzhou, 730070, China.
Kun LiState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, No. 1 Xujiaping, Chengguan District, Lanzhou, 730000, China.
Zengjun LuState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, No. 1 Xujiaping, Chengguan District, Lanzhou, 730000, China. luzengjun@caas.cn.

Funding

Major Program of the Gansu Joint Research Fund 23JRRA1476Start-up Fund for PhD Recruits, Gansu Agricultural University GAU-KYQD-2020-1
6 · The paper itself

Abstract

Canine parvovirus 2 (CPV-2) remains a leading cause of acute infectious gastroenteritis with high global morbidity in dogs. While murine neutralizing monoclonal antibodies (mAbs) are widely used for antiviral therapy, their efficacy is limited by immune rejection in canine recipients. Here, we developed an efficient single B-cell cloning platform to generate canine-derived neutralizing mAbs against CPV-2 and characterized their germline gene usage patterns. Specifically, using biotinylated CPV-2 virions as bait, CPV-2-binding B cells were singly isolated via fluorescence-activated cell sorting (FACS) from peripheral blood mononuclear cells of immunized dogs. The heavy and light chain variable region (VH/VL) sequences were amplified through nested RT-PCR from single B cells, and cloned into canine immunoglobulin heavy/light chain (IgH/IgL) expression vectors. A total of 22 canine-derived mAbs were successfully expressed and purified from suspended ExpiCHO-S cells, and 20 of which demonstrated CPV-2-binding reactivity in enzyme-linked immunosorbent assay (ELISA) or indirect immunofluorescence assay (IFA). Among these, 13 mAbs exhibited neutralizing activity (IC

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralParvovirus, CanineAnimalsB-LymphocytesCloning, MolecularDogsEnzyme-Linked Immunosorbent AssayImmunoglobulin Variable RegionNeutralization TestsParvoviridae InfectionsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Variable RegionCanine neutralizing monoclonal antibodyCanine parvovirus 2Germline gene usageSingle B-cell antibody technology

Identifiers

PMID41876881
PMCPMC13018015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.